Pre-Market Earnings Report for April 18, 2023: JNJ, BAC, LMT, GS, and others.
Today, there are several important reports scheduled for release that could impact the market. I see these upcoming releases as an opportunity for growth in the American stock market, and our robots are currently prioritizing long positions. If I had to choose a robot for this week, I would select the Swing Trader Popular Stocks 4K per position Market Neutral Strategy, which can almost always be found in market-neutral positions and tends to generate the highest profit in any market condition.
Johnson & Johnson (JNJ) is set to report its quarterly earnings for the period ending March 31, 2023. According to a consensus of eight analysts who cover the stock, the company is expected to earn $2.51 per share. This represents a 5.99% decline compared to the same quarter in the previous year. However, JNJ has surpassed analysts' expectations in every quarter of the past year, with its biggest beat occurring in the fourth quarter, where it outperformed consensus estimates by 5.86%.
The Bank of America Corporation (BAC) is expected to report its earnings for the quarter ending March 31, 2023. The consensus earnings per share forecast from 11 analysts who follow the stock is $0.79, which is a 1.25% decrease compared to the same quarter last year. In the 2nd calendar quarter of 2022, BAC missed the consensus earnings per share by -5.19%.
Lockheed Martin Corporation (LMT) is expected to report its quarterly earnings for the period ending March 31, 2023. According to the consensus forecast of 6 analysts following the stock, the aerospace and defense company is expected to report earnings per share of $6.08, which represents a 5.59% decrease compared to the same quarter last year. However, it's worth noting that LMT has exceeded expectations in every quarter of the past year, with the highest beat occurring in the 4th calendar quarter by 5.13%.
Goldman Sachs Group, Inc. (GS) is expected to report earnings for the quarter ending March 31, 2023. The consensus earnings per share forecast from the 8 analysts that follow the stock is $8.14, which represents a significant 24.35% decrease compared to the same quarter last year. In the 4th calendar quarter of 2022, GS missed the consensus earnings per share by -36.76%.
ProLogis, Inc. (PLD) is expected to report a Q1 2023 earnings per share of $1.21, representing an 11.01% increase compared to the same quarter last year. In the 2nd calendar quarter of 2022, PLD missed the consensus earnings per share by -0.89%.
The Bank of New York Mellon Corporation (BK) is expected to report a Q1 2023 earnings per share of $1.09, representing a 26.74% increase compared to the same quarter last year. In the past year, BK has met analyst expectations once and beat expectations the other three quarters.
Ericsson (ERIC) is expected to report a Q1 2023 earnings per share of $0.04, representing a 60.00% decrease compared to the same quarter last year.
Commerce Bancshares, Inc. (CBSH) is expected to report a Q1 2023 earnings per share of $0.91, representing a 1.09% decrease compared to the same quarter last year. In the 3rd calendar quarter of 2022, CBSH missed the consensus earnings per share by -2.02%.
Mercantile Bank Corporation (MBWM) is expected to report a Q1 2023 earnings per share of $1.15, representing a 57.53% increase compared to the same quarter last year. In the past year, MBWM has met analyst expectations once and beat expectations the other three quarters.
JNJ saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for JNJ moved out of overbought territory on March 04, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 59 similar instances where the indicator exited the overbought zone. In of the 59 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for JNJ moved out of overbought territory on March 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on March 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on February 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in of 354 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 259 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.102) is normal, around the industry mean (9.311). P/E Ratio (21.795) is within average values for comparable stocks, (22.655). Projected Growth (PEG Ratio) (1.680) is also within normal values, averaging (2.275). Dividend Yield (0.022) settles around the average of (0.025) among similar stocks. P/S Ratio (6.200) is also within normal values, averaging (3.943).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement